EU Regulatory Procedures In The Pharmaceutical Sector

Law360, New York (July 22, 2010, 1:58 PM EDT) -- On July 1, 2010, the European Union’s General Court upheld a 2005 decision from the European Commission that found that AstraZeneca PLC had abused its dominant position by preventing or delaying the marketing of a generic version of its Losec (omeprazole) product and hindering parallel imports of Losec capsules in certain countries.

Losec is a proton pump inhibitor used in the treatment of acid-related gastric diseases.

In 2005 the EC had found that AstraZeneca had abused its dominant position by: providing deliberately misleading information to patent...
To view the full article, register now.